Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral medication
|
| gptkbp:activeDuring |
gptkb:trifluridine
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availability |
widely available
|
| gptkbp:availableIn |
prescription medication
|
| gptkbp:brand |
gptkb:Viroptic
|
| gptkbp:clinicalTrials |
short-term treatment
included in ophthalmology guidelines studied for efficacy in herpes keratitis |
| gptkbp:contraindication |
conjunctivitis
photophobia eyelid edema hypersensitivity to trifluridine |
| gptkbp:dosageForm |
1 drop in the affected eye every 2 hours while awake
|
| gptkbp:drugInterdiction |
available online
none significant reported poor systemic absorption |
| gptkbp:formulation |
eye drops
|
| gptkbp:healthcare |
provided with prescription
|
| https://www.w3.org/2000/01/rdf-schema#label |
Viroptic
|
| gptkbp:isRecognizedFor |
pregnant women
nursing mothers children under 6 years |
| gptkbp:lastProduced |
1980
|
| gptkbp:manufacturer |
gptkb:Bausch_+_Lomb
|
| gptkbp:marketedAs |
gptkb:Canada
gptkb:United_States Europe |
| gptkbp:offers |
varies by pharmacy
|
| gptkbp:packaging |
bottle
|
| gptkbp:patentExpiration |
2025
|
| gptkbp:patentStatus |
patented
|
| gptkbp:relatedPatent |
herpes simplex virus
viral keratitis |
| gptkbp:researchFocus |
combination therapies
safety in special populations long-term efficacy studies improving delivery methods |
| gptkbp:route |
topical
|
| gptkbp:safetyFeatures |
generally well tolerated
|
| gptkbp:sideEffect |
blurred vision
eye irritation burning sensation redness of the eye |
| gptkbp:storage |
store at room temperature
|
| gptkbp:triggerType |
inhibits viral DNA synthesis
|
| gptkbp:type |
gptkb:trifluridine_ophthalmic_solution
|
| gptkbp:usedFor |
treatment of herpes simplex keratitis
|